Maxim Group reissued their buy rating on shares of PainReform (NASDAQ:PRFX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Maxim Group currently has a $2.00 price objective on the stock.
PainReform Trading Down 3.7 %
Shares of PRFX opened at $0.48 on Wednesday. The stock has a 50-day simple moving average of $0.71 and a 200-day simple moving average of $1.59. PainReform has a 1 year low of $0.45 and a 1 year high of $26.41.
PainReform (NASDAQ:PRFX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($2.72) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On PainReform
PainReform Company Profile
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
See Also
- Five stocks we like better than PainReform
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 6/24 – 6/28
- Roth IRA Calculator: Calculate Your Potential Returns
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.